Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in October 2019 on request of the sponsor.
This medicine is now known as atinumab.
On 19 January 2009, orphan designation (EU/3/08/605) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for recombinant human monoclonal antibody to human Nogo-A protein of the IgG4/k class for the treatment of spinal cord injury.
The sponsorship was transferred to Novartis Europharm Limited, Ireland, in May 2018.
EU/3/08/605: Public summary of positive opinion for orphan designation of recombinant human monoclonal antibody to human Nogo-A protein of the IgG4/k class for the treatment of spinal cord injury (PDF/145.67 KB)
First published: 15/05/2009
Last updated: 16/10/2019
EMEA/COMP/623774/2008 Rev. 1
Recombinant human monoclonal antibody to human Nogo-A protein of the IgG4/kappa class (atinumab)
|Disease / condition||
Treatment of spinal cord injury
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.